Drugs Monitor, Page 32

(01 July 2020) Favipiravir- 66.7%,Day-7 clinical improvement rate [53.7–78.0%]

July 6, 2020

Real-world Experience with Favipiravir for Treatment of COVID-19 in Thailand: Results from a Multi-center Observational Study https://doi.org/10.1101/2020.06.24.20133249 Among 247 COVID-19 patients, 63 (23.0%) received ≥1 dose of favipiravir. Of these, 27.0% required an O2−nasal cannula, 9.5% required non−invasive ventilation and/or… Continue reading "(01 July 2020) Favipiravir- 66.7%,Day-7 clinical improvement rate [53.7–78.0%]"

(01 July 2020) Baricitinib- 12 out of 15 patients recovered with Baricitinib and HCQ combination

July 6, 2020

Use of Baricitinib in Patients with Moderate and Severe COVID-19 https://academic.oup.com/cid/article-abstract/doi/10.1093/cid/ciaa879/5864596 In this retrospective cohort, 15 patients with moderate-severe COVID-19 were treated with baricitinib and hydroxychloroquine. Twelve of 15 recovered, and 3 died. We observed temporally associated clinical improvement following… Continue reading "(01 July 2020) Baricitinib- 12 out of 15 patients recovered with Baricitinib and HCQ combination"

(30 June 2020) Tocilizumab- beneficial effects in severe-to-critically ill patients with COVID-19

July 1, 2020

This manuscript reports findings of observational research of compassionate use of tocilizumab. Tocilizumab was administered to 13 severe-to-critically ill patients with coronavirus disease 2019 (COVID-19) for compassionate use in combination with potential anti-viral agents in those who required an oxygen… Continue reading "(30 June 2020) Tocilizumab- beneficial effects in severe-to-critically ill patients with COVID-19"

(29 June 2020) Baricitinib- induced changes in the immune landscape were associated with a favorable clinical outcome of patients with COVID-19 pneumonia

June 30, 2020

Baricitinib restrains the immune dysregulation in COVID-19 patients https://doi.org/10.1101/2020.06.26.20135319 Evidences that baricitinib-induced changes in the immune landscape were associated with a favorable clinical outcome of patients with COVID-19 pneumonia are provided in this study. A significant reduction in serum levels… Continue reading "(29 June 2020) Baricitinib- induced changes in the immune landscape were associated with a favorable clinical outcome of patients with COVID-19 pneumonia"

(29 June 2020) Remdesivir- (50.4% vs. 45.29%) significantly increased the discharge rate of patients with COVID-19

June 30, 2020

Efficacy and Safety of Remdesivir for COVID-19 Treatment: An Analysis of Randomized, Double-Blind, Placebo-Controlled Trials https://doi.org/10.1101/2020.06.22.20136531 This study is registered at INPLASY (INPLASY202060046). PubMed, Embase, and the Cochrane Central Register of Controlled Trials, from inception to June 11, 2020 for… Continue reading "(29 June 2020) Remdesivir- (50.4% vs. 45.29%) significantly increased the discharge rate of patients with COVID-19"

(28 June 2020) Baricitinib- 9.7% vs 1.3%, discharge rate in the baricitinib arm compared to control arm

June 29, 2020

Retrospective, multicenter study on the impact of baricitinib in COVID-19 moderate pneumonia https://doi.org/10.1016/j.jinf.2020.06.052 113 patients were in the baricitinib-arm, and 78 in the control-arm. The results indicate that the 2-week case fatality rate was significantly lower in the baricitinib-arm compared… Continue reading "(28 June 2020) Baricitinib- 9.7% vs 1.3%, discharge rate in the baricitinib arm compared to control arm"

(28 June 2020) Remdesivir- exhibits favorable safety and PK profiles

June 29, 2020

Safety, Tolerability, and Pharmacokinetics of Remdesivir, an Antiviral for Treatment of COVID-19, in Healthy Subjects https://ascpt.onlinelibrary.wiley.com/doi/epdf/10.1111/cts.12840 This report describes two phase 1 studies that evaluated the safety and pharmacokinetics (PK) of single escalating and multiple intravenous (IV) doses of RDV… Continue reading "(28 June 2020) Remdesivir- exhibits favorable safety and PK profiles"

(26 June 2020) Tocilizumab- 85.9% vs. 71.9% survival among tocilizumab/methylprednisolone/SOC patients vs. SOC

June 27, 2020

Tocilizumab and steroid treatment in patients with COVID-19 pneumonia https://doi.org/10.1101/2020.06.22.20133413 This observational single-center study included patients with COVID-19 pneumonia who were not intubated and received either standard of care (SOC, controls) or SOC plus early (within 3 days from hospital… Continue reading "(26 June 2020) Tocilizumab- 85.9% vs. 71.9% survival among tocilizumab/methylprednisolone/SOC patients vs. SOC"

(24 June 2020) Arbidol- Prophylactic arbidol proved to be protective against COVID-19 in health professionals

June 25, 2020

Effectiveness of Arbidol for COVID-19 Prevention in Health Professionals https://doi.org/10.3389/fpubh.2020.00249 A total of 164 subjects were included in this study, 82 cases in the infected group and 82 controls in the uninfected group, with a median age of 37 years,… Continue reading "(24 June 2020) Arbidol- Prophylactic arbidol proved to be protective against COVID-19 in health professionals"

(24 June 2020) Tocilizumab- single dose helped reduce inflammation, oxygen requirements, vasopressor support, and mortality

June 25, 2020

Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 Pneumonia https://academic.oup.com/cid/articleabstract/doi/10.1093/cid/ciaa812/5861638 In a single-center observational study of tocilizumab in hospitalized patients with SARS-CoV-2 pneumonia clinical and laboratory parameters including oxygen and vasopressor requirements, cytokine profiles, and C-reactive protein (CRP) levels pre-… Continue reading "(24 June 2020) Tocilizumab- single dose helped reduce inflammation, oxygen requirements, vasopressor support, and mortality"